Evidence map›Paper›PMID 42137296›Full record

ArticleMolecular therapy. Advances2026

Chang Li, Anna K Anderson, Anne-Sophie Kuhlmann, Veronica Nelson, Audrey Germond, Hongjie Wang, Aphrodite Georgakopoulou, Sucheol Gil, Jasmin Martinez-Reyes, Andrew Riker and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Durable antiviral protection via directMolecular therapy. Advances · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Chang LiDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
Anna K AndersonDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
Anne-Sophie KuhlmannFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Veronica NelsonFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Audrey GermondUniversity of Washington, Washington National Primate Research Center, Seattle, WA 98195, USA.
Hongjie WangDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
Aphrodite GeorgakopoulouDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
Sucheol GilDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
Jasmin Martinez-ReyesFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Andrew RikerFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Shruthi Shankar RamanFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Jiho KimPAI Life Sciences Inc., Seattle, WA 98102, USA.
Philip NgBaylor College of Medicine, Molecular and Human Genetics, Houston, TX 77030, USA.
Donna PalmerBaylor College of Medicine, Molecular and Human Genetics, Houston, TX 77030, USA.
Michael D AlpertEmmune Inc, Cambridge, MA 02139, USA.
Nickolas SkamangasBoston Children's Hospital, Boston, MA 02115, USA.
Charles BaileyBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Tianling OuBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Christine M FennesseyAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Michael FarzanBoston Children's Hospital, Boston, MA 02115, USA.
Keith R JeromeFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Hans-Peter KiemFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
André LieberDepartment of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
John K BuiFred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
WaNPRC Macaca nemestrina SPF Breeding ColonyU42OD011123 · OD · UNIVERSITY OF WASHINGTON · PI Melissa R Berg, Cindy Buckmaster · 2012 to 2026
$34.4M
WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Clay F. Semenkovich · 2013 to 2026
$27.1M
Primate CoreU19HL156247 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SCADDEN, DAVID T · 2020 to 2024
$14.6M
In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cureR01AI174304 · NIAID · UNIVERSITY OF WASHINGTON · PI HANS-PETER KIEM, ANDRE Michael LIEBER · 2023 to 2026
$4.3M
ENHANCEMENT OF CD4CAR T-CELL PERSISTENCE IN VIVOK08AI183990 · NIAID · UNIVERSITY OF WASHINGTON · PI John K Bui · 2024 to 2026
$637k
Bill & Melinda Gates Foundation INV-017692NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA091842NHLBI NIH HHS U19 HL156247NIAID NIH HHS K08 AI183990NIAID NIH HHS R01 AI174304NIDDK NIH HHS P30 DK020579NIH HHS P51 OD010425NIH HHS U42 OD011123
6 · The paper itself

Abstract

We aim to develop an

Indexed as

eCD4-Iggene therapyhelper-dependent adenovirus vectorshematopoietic stem cellsHIVin vivomobilizationrhesus macaquesSIV

Identifiers

PMID42137296
PMCPMC13148906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.